Key Takeaways
- NAD+ (nicotinamide adenine dinucleotide) is an essential coenzyme involved in energy metabolism, DNA repair, and cellular signaling that is depleted by chronic substance use.
- IV NAD+ therapy has been used in addiction settings since the 1960s but has a limited formal evidence base; most claims rest on mechanistic plausibility, preclinical data, and observational reports rather than randomized controlled trials.
- Chronic substance use depletes NAD+ through multiple mechanisms, and restoration of NAD+ levels may support mitochondrial function, neuronal energy production, and sirtuin-mediated cellular repair in recovery.
- The limited available clinical data suggests IV NAD+ may reduce withdrawal severity and craving in early recovery, but randomized controlled trials with adequate sample sizes and control conditions are lacking.
- NAD+ therapy is best understood as a nutritional support adjunct in early recovery, not as a substitute for evidence-based addiction treatment including medication-assisted treatment and behavioral therapy.
- Trust SoCal offers comprehensive, evidence-based addiction treatment in Orange County incorporating nutritional support; call (949) 280-8360 to learn about our medically supervised programs.
Introduction: NAD+ from Biochemistry to Wellness Marketing
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme present in every living cell, playing fundamental roles in energy metabolism, DNA repair, and regulation of numerous cellular processes including gene expression through sirtuin enzymes and calcium signaling through CD38. NAD+ and its reduced form NADH are central to the mitochondrial electron transport chain, shuttling electrons between metabolic reactions to generate ATP, the cellular energy currency. Without sufficient NAD+, mitochondrial function deteriorates, cellular energy production fails, and the numerous enzymatic processes that require NAD+ as a cofactor cannot proceed adequately. NAD+ depletion is recognized as a contributor to aging, metabolic disease, and neurodegenerative conditions.
Over the past decade, NAD+ has transitioned from an obscure biochemical cofactor to a prominent wellness supplement and increasingly aggressive commercial treatment offering, marketed for anti-aging, cognitive enhancement, athletic performance, and most relevantly for this review, addiction recovery and detoxification. Clinics offering intravenous NAD+ infusions have proliferated across Southern California and the United States, with treatments marketed for "brain restoration" after addiction, rapid opioid detoxification, alcohol withdrawal management, and general recovery acceleration. These claims are promoted with compelling biological narratives about NAD+ depletion in addiction and cellular repair in recovery, but the formal clinical evidence base is substantially thinner than the marketing suggests.
At Trust SoCal in Fountain Valley, we approach NAD+ therapy with the same balanced evidence-based perspective we apply to all emerging treatment options: acknowledging the genuine biological rationale and preliminary evidence while being honest about the limitations of the current research and the commercial overreach of many NAD+ therapy claims. Understanding what NAD+ therapy can and cannot offer helps patients and families make informed decisions about how to invest limited treatment resources. For guidance on building an evidence-based treatment plan, contact us at (949) 280-8360.
The Biology of NAD+ Depletion in Addiction
The rationale for NAD+ therapy in addiction rests on well-established biochemistry: chronic substance use depletes NAD+ through multiple mechanisms, and this depletion may contribute to some of the neurological, metabolic, and psychological features of addiction and withdrawal. Alcohol is the most extensively studied substance in this context. Alcohol metabolism by alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) consumes large amounts of NAD+, converting it to NADH. This NADH excess and NAD+ depletion disrupts normal mitochondrial function, impairs fatty acid oxidation and gluconeogenesis, and alters the activity of sirtuin enzymes that depend on NAD+ for their histone deacetylase activity. Chronic heavy alcohol use can produce a state of profound NAD+ deficiency that contributes to liver disease, metabolic dysregulation, and potentially to some of the neurological consequences of alcoholism.
Opioids, stimulants, and other substances also affect NAD+ metabolism, though through different mechanisms. Chronic opioid use appears to dysregulate mitochondrial function through mu-opioid receptor-mediated effects on cellular signaling, potentially affecting NAD+ dependent processes. Methamphetamine produces oxidative stress that consumes NAD+ through poly(ADP-ribose) polymerase (PARP) activation, an enzyme that uses NAD+ as a substrate to repair oxidatively damaged DNA. The net result of chronic substance use across multiple drug classes appears to be a state of relative cellular energy deficit that may contribute to the fatigue, cognitive impairment, emotional dysregulation, and physical depletion that characterize post-acute withdrawal syndrome.
In theory, restoring NAD+ levels during early recovery could support mitochondrial energy production, reduce oxidative stress, enhance sirtuin-mediated cellular repair including epigenetic normalization, and potentially restore neuronal function in regions affected by substance-induced damage. This biological narrative is compelling and scientifically coherent. The question is whether intravenous NAD+ administration in clinical settings actually delivers the concentrations and distribution to target tissues needed to produce meaningful clinical effects, and whether the clinical effects observed in addiction settings are sufficiently robust and reproducible to justify the current enthusiasm and expense.
NAD+ cannot be administered orally in a form that significantly raises intracellular NAD+ levels because it is broken down in the gastrointestinal tract. Precursors including nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) can raise NAD+ levels when taken orally and have more accessible evidence bases for general health applications, though addiction-specific evidence is limited for these forms as well.
NAD+ Metabolic Pathways Relevant to Addiction Recovery
Understanding the cellular roles of NAD+ helps clarify why its depletion in addiction might be clinically significant and why restoration might support recovery.
- Mitochondrial Energy Production: NAD+ is essential for the TCA cycle and electron transport chain; depletion impairs ATP generation and can produce the fatigue and cognitive fog common in early recovery.
- Sirtuin Activation: Sirtuins are NAD+-dependent deacetylases that regulate gene expression, mitochondrial biogenesis, and stress responses; their impairment in NAD+ depletion may affect neuronal resilience.
- PARP-1 Activation: PARP-1 uses NAD+ as a substrate for DNA repair following oxidative damage from substance use; very high PARP-1 activity can paradoxically deplete NAD+ further, creating a vicious cycle.
- Tryptophan-Kynurenine Pathway: The primary de novo NAD+ synthesis pathway; chronic inflammation (common in addiction) diverts tryptophan toward kynurenines rather than NAD+, potentially reducing NAD+ production.
- SIRT1 and Brain-Derived Neurotrophic Factor: SIRT1, a NAD+-dependent deacetylase, promotes BDNF expression; impaired SIRT1 activity from NAD+ depletion may reduce BDNF-mediated neuroplasticity during recovery.
The Clinical Evidence: What Research Actually Shows
The clinical evidence base for NAD+ therapy in addiction is genuinely limited, consisting primarily of case series, small uncontrolled studies, and practitioner reports rather than randomized controlled trials. The earliest systematic clinical use of NAD+ for addiction was developed by Dr. William Hitt in Mexico in the 1960s and 1970s, who reported that high-dose IV NAD+ appeared to reduce opioid and alcohol withdrawal severity. This early clinical experience attracted limited scientific attention due to the absence of controlled trials. More recently, the Springfield Wellness Center in Louisiana has treated thousands of patients with IV NAD+ for addiction and early recovery and has published observational data suggesting improvements in withdrawal symptoms, craving, anxiety, and mood, but without control groups or blinding.
A small randomized pilot study published in the Journal of Alternative and Complementary Medicine by Mestayer and colleagues found that patients receiving IV NAD+ plus standard care showed significantly greater reductions in withdrawal symptoms and craving at five days compared to standard care alone. The sample size was small (28 participants), the follow-up period was brief, and the trial lacked blinding, but the findings provided preliminary support for a controlled investigation. Several additional small studies in alcohol use disorder and opiate withdrawal have reported positive findings with IV NAD+, but methodological limitations including absence of randomization, small samples, and short follow-up periods preclude definitive conclusions.
The honest assessment of the current evidence is that NAD+ therapy has a plausible biological rationale for benefiting addiction recovery, particularly in the context of nutritional and cellular energy deficits in early recovery, and preliminary clinical signals are positive but far from conclusive. The field needs well-designed randomized controlled trials with adequate sample sizes, appropriate control conditions, validated outcome measures, and sufficient follow-up periods to determine whether NAD+ therapy adds meaningful clinical benefit beyond the improvements achieved with standard evidence-based care. Until such trials are completed, claims of dramatic therapeutic benefit from commercial NAD+ providers should be viewed skeptically.
NAD+ infusion therapy is often priced at $500 to $1,500 per infusion, with treatment courses of multiple infusions costing $3,000 to $10,000 or more. This significant financial investment should be made with a clear-eyed assessment of the limited evidence base. NAD+ therapy is not covered by most insurance plans for addiction indications. Directing financial resources toward evidence-based treatments with stronger evidence may produce better outcomes.
What NAD+ Therapy Can and Cannot Do in Recovery
A balanced understanding of NAD+ therapy requires honesty about both its potential contributions and its clear limitations. On the positive side, IV NAD+ therapy appears to be generally well-tolerated with a good safety profile when administered by qualified clinicians. The most common adverse effects include nausea, chest tightness, and flushing that typically resolve with dose reduction or slowing of the infusion rate. Serious adverse effects are rare. Some patients report meaningful subjective improvements in energy, mood, and mental clarity during the course of NAD+ treatment, which can support engagement with the therapeutic components of recovery. For patients with significant nutritional deficiencies and metabolic dysfunction from chronic substance use, addressing these deficits through comprehensive nutritional support that might include NAD+ is a reasonable clinical consideration.
On the limitation side, it is essential to be clear that NAD+ therapy does not directly address the psychological dimensions of addiction, does not modify the neural circuits that drive craving and compulsive use, does not treat the underlying trauma or co-occurring psychiatric conditions that often drive substance use, and has not been shown to produce sustained reductions in substance use or improve long-term recovery outcomes in rigorous trials. Claims that NAD+ represents a form of detoxification that rapidly eliminates withdrawal and cravings are not supported by the clinical evidence. The idea that addiction can be addressed primarily through cellular metabolic restoration, without comprehensive psychological and social treatment, reflects a fundamental misunderstanding of addiction as a condition.
The most appropriate conceptual framing for NAD+ therapy is as one component of a comprehensive nutritional and medical support strategy in early recovery, not as a primary or standalone addiction treatment. In this framing, NAD+ infusions might supplement a broader approach to nutritional rehabilitation that includes thiamine supplementation (critically important in alcohol use disorder to prevent Wernicke's encephalopathy), B-vitamin supplementation, amino acid repletion, and normalization of sleep and physical activity. At Trust SoCal, we take a comprehensive approach to the medical and nutritional dimensions of early recovery while grounding our primary treatment in evidence-based behavioral and pharmacological interventions. Contact us at (949) 280-8360.
NAD+ in the Context of Comprehensive Addiction Care
For individuals considering NAD+ therapy as part of their addiction recovery, the decision should be made in the context of a comprehensive treatment plan developed with qualified addiction medicine clinicians. The first priority should always be ensuring that the most evidence-based treatments are in place: for opioid use disorder, this means medication-assisted treatment with buprenorphine or naltrexone; for alcohol use disorder, it means medically supervised withdrawal management and ongoing pharmacotherapy with naltrexone or acamprosate; for all substance use disorders, it means appropriate behavioral therapies including CBT, motivational interviewing, and relapse prevention planning.
If these foundational elements are in place and a patient is interested in adjunctive approaches to address the metabolic and cellular health dimensions of recovery, NAD+ therapy may be a reasonable consideration, particularly in the early weeks of recovery when the biological disruption from chronic substance use is most acute. Patients should seek NAD+ therapy from licensed medical providers who conduct appropriate pre-treatment assessments and who are transparent about the current state of evidence. Receiving NAD+ therapy in the context of a clinic that also provides comprehensive addiction treatment, rather than at a standalone wellness center, ensures that the therapy is integrated appropriately into overall care.
Trust SoCal's comprehensive addiction treatment programs in Fountain Valley, Orange County, address the full complexity of substance use disorders through individualized, multidisciplinary care. Our medical team evaluates the nutritional and cellular health needs of each patient in early recovery and incorporates appropriate nutritional support into individualized treatment plans. Our clinical team delivers evidence-based behavioral therapies that address the psychological, social, and behavioral dimensions of addiction that nutritional interventions cannot address alone. We invite you to call us at (949) 280-8360 or visit our facility at 16537 Elm Cir, Fountain Valley, CA 92708, to learn how our comprehensive approach can support your recovery.
NAD+ is a molecule with genuinely important roles in cellular health, and its depletion by chronic substance use is real. Whether IV supplementation produces meaningful clinical benefits in addiction recovery beyond good nutritional care is a question that deserves rigorous scientific investigation rather than commercial exploitation.
— Addiction medicine perspective on nutritional support in early recovery
Evaluating NAD+ Clinics: Questions to Ask
Given the significant commercial activity around NAD+ therapy for addiction, it is important for patients and families to evaluate NAD+ providers with appropriate rigor. Key questions to ask prospective NAD+ therapy providers include: What evidence supports the specific claims being made about NAD+ for addiction? What pre-treatment assessment is conducted, and who performs it? Is the prescribing clinician board-certified in addiction medicine or a related specialty? How does NAD+ therapy fit into a comprehensive addiction treatment plan, and what behavioral therapy or counseling is included or recommended? What monitoring is conducted during infusions, and what protocols exist if adverse effects occur?
Red flags in NAD+ therapy marketing include claims of "curing" addiction or producing "complete" elimination of withdrawal without additional treatment, guarantees of specific outcomes, marketing that emphasizes NAD+ as an alternative rather than an adjunct to comprehensive addiction treatment, very high prices relative to other treatment options without corresponding evidence base, and providers who do not require a medical evaluation before administering IV therapy. Facilities that offer NAD+ exclusively or primarily without comprehensive addiction treatment programming may not be the best choice for individuals seeking genuine addiction recovery support.
Trust SoCal's clinical team is available to help patients evaluate emerging and complementary treatment options with scientific literacy and clinical wisdom. We believe patients deserve honest, nuanced information about what the evidence supports and where the gaps are, rather than either reflexive dismissal of all emerging treatments or uncritical acceptance of commercially motivated claims. If you are considering NAD+ therapy or any other emerging treatment and want a clinical perspective grounded in evidence-based addiction medicine, we invite you to call (949) 280-8360 or visit us at 16537 Elm Cir, Fountain Valley, CA 92708.
Trust SoCal Editorial Team, Clinical Review Board
Editorial & Clinical Review